A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

September 1, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

March 1, 2024

Conditions
Cerebral StrokeThrombosis, Deep VeinPulmonary Embolism
Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03804125 - A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery | Biotech Hunter | Biotech Hunter